Education
About Us
Working with TipRanks
Follow Us
Gentian Diagnostics ASA (DE:6FK)
FRANKFURT:6FK
6FK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€3.20 - €5.42
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€71.23M
Enterprise Value€909.94M
Total Cash (Recent Filing)€88.74M
Total Debt (Recent Filing)€4.34M
Price to Earnings (P/E)20.0
Beta0.35
Next Earnings
Oct 23, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding15,422,350
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Gentian Diagnostics ASA News
6FK FAQ
What was Gentian Diagnostics ASA’s price range in the past 12 months?
Gentian Diagnostics ASA lowest stock price was €3.20 and its highest was €5.42 in the past 12 months.
What is Gentian Diagnostics ASA’s market cap?
Gentian Diagnostics ASA’s market cap is €71.23M.
When is Gentian Diagnostics ASA’s upcoming earnings report date?
Gentian Diagnostics ASA’s upcoming earnings report date is Oct 23, 2025 which is in 21 days.
How were Gentian Diagnostics ASA’s earnings last quarter?
Gentian Diagnostics ASA released its earnings results on Jul 10, 2025. The company reported -€0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.011.
Is Gentian Diagnostics ASA overvalued?
According to Wall Street analysts Gentian Diagnostics ASA’s price is currently Overvalued.
Does Gentian Diagnostics ASA pay dividends?
Gentian Diagnostics ASA does not currently pay dividends.
What is Gentian Diagnostics ASA’s EPS estimate?
Gentian Diagnostics ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gentian Diagnostics ASA have?
Gentian Diagnostics ASA has 15,422,350 shares outstanding.
What happened to Gentian Diagnostics ASA’s price movement after its last earnings report?
Gentian Diagnostics ASA reported an EPS of -€0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.938%.
Which hedge fund is a major shareholder of Gentian Diagnostics ASA?
Currently, no hedge funds are holding shares in DE:6FK
Company Description
Gentian Diagnostics ASA
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.